Tonix Q3 net loss $28M ($1.83/shr); cash drops to $6.9M; phase 3 fibromyalgia data due Dec 2023

Tonix Pharmaceuticals Holding Corp.

2023-Q3 EPS reported -$7.40 revenue$3,989,000

Net product revenue of $4.0M in first quarter after acquiring Zembrace/Tosymra in June 2023.
Cash and equivalents $6.9M at Sep 30, 2023 vs $120.2M at Dec 31, 2022.
Public offerings in Aug and Sep 2023 raised net proceeds of $6.3M and $4.0M respectively.
Topline Phase 3 RESILIENT trial (TNX-102 SL) for fibromyalgia expected late December 2023.
Topline Phase 2 PREVENTION study (TNX-1900) for chronic migraine expected early December 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tonix Pharmaceuticals Holding Corp. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 9, 2023, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended September 30, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001839882-23-030323

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.